EUDA Expands Wellness Product Portfolio With A Next-Generation Immune Health Supplement
EUDA Health Holdings (NASDAQ: EUDA), a Singapore-based healthcare provider, has secured exclusive worldwide distribution rights for a next-generation immune health supplement from Chemokine Pte. Ltd. The supplement, branded as Euda Helixé, will initially launch in Singapore, Malaysia, and China.
The advanced formulation features premium ingredients including deer placenta, L-Glutathione, and marine collagen, utilizing epigenetic technology to modulate gene expression. The supplement aims to enhance metabolism, boost vitality, and support longevity through its specialized capsule delivery system.
CEO Alfred Lim projects potential sales of 500,000 bottles within the next 12 months, representing a significant opportunity for revenue diversification.
EUDA Health Holdings (NASDAQ: EUDA), provider sanitario con sede a Singapore, ha ottenuto i diritti esclusivi di distribuzione mondiale per un integratore immunitario di nuova generazione sviluppato da Chemokine Pte. Ltd. Il prodotto, commercializzato con il nome Euda Helixé, sarà lanciato inizialmente a Singapore, Malesia e Cina.
La formulazione avanzata contiene ingredienti di pregio come placenta di cervo, L-Glutatione e collagene marino, sfruttando tecnologie epigenetiche per modulare l'espressione genica. L'integratore è progettato per migliorare il metabolismo, aumentare la vitalità e sostenere la longevità grazie a un sistema di somministrazione in capsule studiato appositamente.
Il CEO Alfred Lim prevede vendite potenziali di 500.000 flaconi nei prossimi 12 mesi, rappresentando una notevole opportunità di diversificazione dei ricavi.
EUDA Health Holdings (NASDAQ: EUDA), proveedor de servicios de salud con sede en Singapur, ha obtenido los derechos exclusivos de distribución mundial de un suplemento inmunitario de nueva generación desarrollado por Chemokine Pte. Ltd. El suplemento, con la marca Euda Helixé, se lanzará inicialmente en Singapur, Malasia y China.
La formulación avanzada incluye ingredientes de primera calidad como placenta de ciervo, L-Glutatión y colágeno marino, y utiliza tecnología epigenética para modular la expresión génica. El suplemento busca mejorar el metabolismo, aumentar la vitalidad y apoyar la longevidad mediante un sistema de administración en cápsulas especializado.
El CEO Alfred Lim proyecta ventas potenciales de 500.000 botellas en los próximos 12 meses, lo que supone una importante oportunidad para diversificar los ingresos.
EUDA Health Holdings (NASDAQ: EUDA)는 싱가포르에 본사를 둔 헬스케어 기업으로, Chemokine Pte. Ltd.가 개발한 차세대 면역 건강 보조제에 대한 전 세계 독점 유통 권한을 확보했습니다. 해당 보조제는 Euda Helixé라는 브랜드로 먼저 싱가포르, 말레이시아, 중국에서 출시될 예정입니다.
이 고급 제형은 사슴 태반, L-글루타치온, 해양 콜라겐 등 프리미엄 성분을 포함하며, 후생유전학(에피제네틱) 기술을 활용해 유전자 발현을 조절합니다. 이 보조제는 특수 캡슐 전달 시스템을 통해 신진대사를 개선하고 활력을 높이며 장수 지원을 목표로 합니다.
CEO 알프레드 림은 향후 12개월 내에 50만 병 판매를 예상하고 있으며, 이는 수익 다각화의 중요한 기회가 될 것으로 보입니다.
EUDA Health Holdings (NASDAQ: EUDA), prestataire de santé basé à Singapour, a obtenu les droits exclusifs de distribution mondiale d'un supplément immunitaire de nouvelle génération développé par Chemokine Pte. Ltd. Le produit, commercialisé sous la marque Euda Helixé, sera lancé initialement à Singapour, en Malaisie et en Chine.
La formulation avancée comprend des ingrédients de qualité supérieure tels que placenta de cerf, L‑Glutathion et collagène marin, et utilise une technologie épigénétique pour moduler l'expression génique. Ce supplément vise à améliorer le métabolisme, renforcer la vitalité et soutenir la longévité grâce à un système d'administration en gélules spécialisé.
Le PDG Alfred Lim prévoit des ventes potentielles de 500 000 flacons au cours des 12 prochains mois, représentant une opportunité significative de diversification des revenus.
EUDA Health Holdings (NASDAQ: EUDA), ein in Singapur ansässiger Gesundheitsdienstleister, hat die weltweiten Exklusivvertriebsrechte für ein neuartiges Immunpräparat von Chemokine Pte. Ltd. gesichert. Das Präparat wird unter der Marke Euda Helixé zunächst in Singapur, Malaysia und China eingeführt.
Die fortschrittliche Formulierung enthält hochwertige Inhaltsstoffe wie Hirschplazenta, L-Glutathion und Meereskollagen und nutzt epigenetische Technologien zur Modulation der Genexpression. Das Supplement zielt darauf ab, den Stoffwechsel zu verbessern, die Vitalität zu steigern und Langlebigkeit zu unterstützen – verabreicht über ein spezialisiertes Kapselsystem.
CEO Alfred Lim prognostiziert potenzielle Verkäufe von 500.000 Flaschen innerhalb der nächsten 12 Monate und sieht darin eine bedeutende Chance zur Diversifizierung der Einnahmen.
- Secured exclusive worldwide distribution rights for an advanced immune health supplement
- Projected sales of 500,000 bottles in the next 12 months indicate significant revenue potential
- Strategic expansion of wellness product portfolio with innovative gene-modulating technology
- Initial launch in three key Asian markets with plans for future expansion
- Success depends on unproven market acceptance of new supplement technology
- Potential competition from established supplement manufacturers in target markets
Insights
EUDA expands revenue potential with exclusive distribution rights for a gene-modulating supplement, targeting 500,000 bottles in first year.
EUDA Health's acquisition of exclusive worldwide distribution rights for Chemokine's next-generation immune supplement represents a strategic expansion of their wellness portfolio. The supplement, to be marketed as Euda Helixé, employs epigenetic technology designed to modulate gene expression—activating beneficial genes while silencing harmful ones.
The formulation contains seven premium ingredients including deer placenta, L-Glutathione, and marine collagen, delivered via a specialized capsule system that protects active compounds from stomach acid degradation. This technology aims to maximize absorption where it's most effective.
From a revenue perspective, management projects potential sales of 500,000 bottles in the next 12 months. This initiative aligns with EUDA's strategy to diversify revenue streams beyond their core non-invasive healthcare services in Singapore, Malaysia, and China.
The product's scientific credibility is anchored by Chemokine's founder, Professor Kah Meng Lim, who holds a Ph.D. in Molecular Medicine from the National University of Singapore and has research experience with A*STAR. This academic backing provides some differentiation in the crowded supplement market.
While the announcement signals potential new revenue sources, investors should note that the supplement market is highly competitive, and actual sales performance will depend on marketing execution, pricing strategy, and consumer adoption rates across their initial target markets before any planned expansion.
SINGAPORE, Aug. 26, 2025 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a leading Singapore-based non-invasive healthcare provider in Asia focused on Singapore, Malaysia, and China, today announced that its wholly-owned subsidiary, EUDA Health Pte. Ltd., has secured exclusive worldwide distribution rights for a next-generation immune health supplement (the “Supplement”) from Chemokine Pte. Ltd. (“Chemokine”), a Singapore-based biotech company focused on molecular supplements and gene modulating formulations.
EUDA and its subsidiaries will market and sell the Supplement under the brand name, Euda Helixé, initially in Singapore, Malaysia, and China before expanding it to other markets in the future. The addition of the Supplement will further reinforce EUDA’s wellness product portfolio as it drives the transformation of the health and wellness landscape in the region.
The Supplement is an advanced formulation designed to modulate gene expression by activating beneficial genes while silencing harmful ones. Leveraging cutting-edge epigenetic technology, the Supplement enhances metabolism, boosts vitality, supports longevity, and is positioned as a foundational pillar in EUDA’s growing wellness product suite.
The Supplement builds on prior scientific advancements and proven formulation platforms to deliver molecular-level wellness support. The Supplement combines premium-grade ingredients including:
· Deer placenta
· L-Glutathione
· Astaxanthin
· Marine collagen
· Sea-Buckthorn oil
· Grape seed oil
· New Zealand refined avocado oil
Its capsule delivery system ensures active ingredients survive stomach acid and are released where absorption is maximized, enhancing efficacy.
Key Benefits of the Supplement
1. Gene-activated metabolic enhancement
2. Sustained energy and vigor via time-release delivery
3. Collagen-based youthfulness and skin regeneration
4. Longevity support through stem cell regeneration pathways
Chemokine was founded by Professor Kah Meng Lim, a molecular medicine researcher with deep scientific roots. Prof. Lim earned his Ph.D. in Molecular Medicine from the National University of Singapore and spent years in research roles under Singapore’s national R&D agency, A*STAR. His work bridges academic science and consumer health innovation, and he is widely respected for translating complex biological discoveries into practical health applications.
Mr. Alfred Lim, CEO of EUDA, commented, “Securing exclusive distribution rights for such a special product will reinforce our portfolio of wellness product offerings and further diversify our revenue streams. The Supplement positions EUDA at the forefront of molecular precision wellness, leveraging breakthrough gene activation technology. With our strong regional ecosystem and distribution capabilities, we believe that it is possible to generate sales of about 500,000 bottles over the next 12 months.”
About EUDA Health Holdings Limited
EUDA Health Holdings Limited (NASDAQ: EUDA) is a Singapore-based leading non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia, and China. The Company aims to become a market leader in non-invasive and preventive healthcare, with a strategic focus on the fast-growing longevity sector. Our mission is to address the evolving healthcare needs of over 1.8 billion people across the region which is experiencing significant demographic shifts as more than
Forward Looking Statements
This document may contain forward-looking statements regarding risks and uncertainties. These statements usually use forward-looking words, such as the words “estimates,” “projected,” “expects,” “envisions,” “anticipates,” “forecasts,” “plans,” “intends,” “believes,” “seeks,” “may,” “will,” “should,” “future,” “propose” and variations of these words or similar expressions (or the negative versions of such words or expressions). These forward-looking statements are not guarantees of future performance, conditions or results, and involve a number of known and unknown risks, uncertainties, assumptions and other important factors, many of which are outside EUDA’s control, that could cause actual results or outcomes to differ materially from those discussed in the forward-looking statements. You should not overly rely on forward-looking statements that are only applicable to the date of publication of this document. These forward-looking statements are based on information from EUDA as well as other sources that we believe are reliable. The Company does not undertake any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.
Contact:
Christensen Advisory
Linda Bergkamp
Phone: +1-480-614-3004
E-mail: linda.bergkamp@christensencomms.com
FAQ
What is the new EUDA Health supplement and what does it do?
Where will EUDA Health (NASDAQ: EUDA) distribute its new supplement?
What are the projected sales for EUDA's new supplement?
What key ingredients are in the EUDA Health supplement?
Who developed EUDA Health's new supplement?
